Tuesday, September 13, 2022

Rebate walls may thwart biosimilar savingsRebate walls may thwart biosimilar savingsRebate walls may thwart biosimilar savings

Rebate walls may thwart biosimilar savings

Humira biosimilars are expected to reduce annual pharmaceutical expenditures by $5 billion, but they may be delayed by rebate strategies.



from Section Page News - Modern Healthcare https://ift.tt/oQNBDd0
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)